育龄女性癌症幸存者中感知不孕与避孕使用的关系
这项横断面研究纳入483名18-40岁女性癌症幸存者,通过在线问卷评估感知生育力与避孕使用的关系。84%的参与者使用避孕措施,49.7%使用世界卫生组织I和II类高效方法。自感不孕的幸存者不使用避孕的比例高于自感生育力与同龄人相当或更高的幸存者(患病率比4.0,95%CI 2.5-7.4)。在调整临床不孕的中介分析中,既往化疗与不使用避孕之间的关联有59%由感知不孕解释。
要点
- 84%的育龄女性癌症幸存者使用避孕措施,49.7%使用WHO I/II类高效方法。
- 自感不孕者不使用避孕的比例是自感生育力相当或更高者的4.0倍(95%CI 2.5-7.4)。
- 既往化疗与不使用避孕的关联中,59%由感知不孕解释。
核心结论
- 育龄女性癌症幸存者避孕使用率较高,但自感不孕者使用避孕的可能性更低。
- 临床医生应在整个生存期就生育潜力及影响生殖决策的因素(包括避孕有效性和无激素避孕)对幸存者进行咨询。
研究设计与样本
- 横断面研究,参与者来自美国两个州癌症登记处、医生转诊和癌症幸存者倡导组织。
- 共纳入483名18-40岁女性幸存者,通过在线问卷收集数据。
主要发现
- 84%的参与者使用避孕措施,49.7%使用世界卫生组织I和II类高效方法(手术绝育、宫内节育器、避孕植入剂、复方激素避孕药、醋酸甲羟孕酮、孕激素-only片剂、避孕隔膜)。
- 自感不孕的幸存者不使用避孕的比例高于自感生育力与同龄人相当或更高的幸存者(患病率比4.0,95%CI 2.5-7.4)。
- 在调整临床不孕的中介分析中,既往化疗与不使用避孕之间的关联有59%由感知不孕解释。
- 使用I/II类方法的最常见原因是避孕有效性(n=62,25.8%)和易用性(n=50,20.8%);使用效果较差的III/IV类方法的主要原因是无激素(n=81,49.7%)。
临床怎么用
- 作者建议临床医生在整个生存期就生育潜力结合既往癌症治疗进行咨询,并就避孕有效性和无激素避孕等影响生殖决策的因素进行讨论。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To estimate the association between perceived fertility potential and contraception use and to characterize factors important in contraceptive decision making in reproductive-age, female cancer survivors. DESIGN: Cross-sectional study. SETTING: Participants were from two state cancer registries, physician referrals, and cancer survivor advocacy groups in the United States. PATIENT(S): A total of 483 female survivors aged 18-40 years. INTERVENTION(S): Online questionnaire. MAIN OUTCOME MEASURE(S): Contraception use. RESULT(S): Eighty-four percent of participants used contraception; 49.7% used highly effective, World Health Organization tiers I and II methods (surgical sterilization, intrauterine devices, contraceptive implant, combined hormonal contraceptives, medroxyprogesterone acetate, progestin-only pills, contraceptive diaphragm). Contraception non-use was more common among survivors who perceived themselves to be infertile, compared with survivors who perceived themselves to be as or more fertile than similarly aged peers (prevalence ratio 4.0, 95% confidence interval 2.5-7.4). In mediation analysis that adjusted for clinical infertility, 59% of the association between prior chemotherapy and contraception non-use was explained by perceived infertility. Contraception efficacy (n = 62, 25.8%) and ease of use (n = 50, 20.8%) were the most cited reasons for using tier I/II methods; compared with lack of hormones (n = 81, 49.7%) as the predominant reason for using less-effective, tier III/IV methods. CONCLUSION(S): Although female, reproductive-age cancer survivors had high uptake of contraception, those who perceived themselves to be infertile were less likely to use contraception. Throughout survivorship, clinicians should counsel survivors on fertility potential in the context of their prior cancer treatments and on factors, including contraceptive efficacy and hormone-free contraception, that inform reproductive decision making in this population.
引用
- Hadnott TN, Stark SS, Medica A, et al. Perceived infertility and contraceptive use in the female, reproductive-age cancer survivor. Fertil Steril. 2019. PMID: 30929732. doi:10.1016/j.fertnstert.2018.12.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。